Status:
COMPLETED
Piracetam for Treatment Tardive Dyskinesia
Lead Sponsor:
Beersheva Mental Health Center
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Tardive Dyskinesia
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The mechanism involved in the development of tardive dyskinesia (TD) is complicated. It now seems that several neurotransmitter systems may be affected, including dopaminergic, noradrenergic, gamma-am...
Detailed Description
We intend to examine 40 inpatients, aged 18-75 years old, suffering from TD and its variants. Criteria for inclusion into the study will be: a) DSM-IV diagnosis of tardive dyskinesia; b) stable psycho...
Eligibility Criteria
Inclusion
- age 18-75
- DSM-IV diagnosis of tardive dyskinesia
- stable psychotropic regimen of a month prior to entry
- duration of TD for at least one year
- hospitalization at our Center
Exclusion
- family history of Huntington's disease
- drug or alcohol abuse
- concurrent medial illness or neurological disorder that may have contributed to the diagnosis of TD
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00190008
Start Date
August 1 2003
Last Update
November 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beersheva Mental Health Center
Beersheva, Israel